Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 5/20 | 0.62 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047752 | 0.93 | MAPKAPK5 (0.63) | MAPKAPK5ZAP70MITFRAD52FGFR1 | |
| SCHEMBL1043477 | 0.90 | MAPKAPK5 (0.76) | MAPKAPK5RAD52PTK2KDM1AJAK2 | |
| SCHEMBL1044506 | 0.89 | MAPKAPK5 (0.60) | MAPKAPK5ZAP70FGFR1KDM1ACCNA2 | |
| SCHEMBL1045465 | 0.89 | MAPKAPK5 (0.60) | MAPKAPK5ZAP70FGFR1KDM1ACCNA2 | |
| SCHEMBL1047036 | 0.88 | MAPKAPK5 (0.62) | MAPKAPK5FGFR1PTK2CCNA2CDK2 | |
| SCHEMBL1047106 | 0.86 | MAPKAPK5 (0.60) | MAPKAPK5SYKCDK6JAK2ROCK2 | |
| SCHEMBL1046099 | 0.84 | MAPKAPK5 (0.58) | MAPKAPK5FGFR1SYKCCNA2CDK2 | |
| SCHEMBL10134497 | 0.84 | MAPKAPK5 (0.62) | MAPKAPK5ZAP70MITFRAD52FGFR1 | |
| SCHEMBL1048035 | 0.84 | MAPKAPK5 (0.57) | MAPKAPK5FGFR1CCNA2CDK2CCND3 | |
| SCHEMBL1082113 | 0.82 | MAPKAPK5 (0.58) | MAPKAPK5ZAP70FGFR1CDK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | claimed |
| EP-2086540-B8 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-03-02 | — | — | EP | claimed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | claimed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| EP-2086540-B8 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2086540-B1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 15/4885ZAP70 1324/4885MITF 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.